What is AllExcel?
AllExcel is at the forefront of nanomedicine, having developed a proprietary platform technology known as "TheraCour." This micelle-forming, self-assembling polymeric material is engineered for highly targeted drug delivery, capable of directing therapeutic agents to specific cancer cells, bacterial cells, or virus particles while sparing healthy tissues. TheraCour's unique address-based targeting mechanism allows for precise control over a drug's pharmacokinetic profile, enabling tailored lifetimes ranging from hours to weeks, which significantly enhances patient compliance. Furthermore, the platform supports diverse delivery routes, including injectable, transdermal, topical ocular, and oral administration, streamlining the drug development formulation stage. TheraCour also facilitates the encapsulation of therapeutic cells for treating degenerative diseases such as Diabetes, Liver Disease, Parkinson's Disease, and neurodegeneration, protecting them within a gel matrix for implantation and minimizing host-related cell death.
How much funding has AllExcel raised?
AllExcel has raised a total of $467K across 2 funding rounds:
Debt
$150K
Debt
$317K
Debt (2020): $150K with participation from PPP
Debt (2021): $317K led by PPP
Key Investors in AllExcel
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for AllExcel?
With its large-scale late-stage funding and a recent major strategic investment, AllExcel is positioned for significant growth and commercialization. The company's focus on its TheraCour platform, which has demonstrated inherent safety and high effectiveness in preclinical models, suggests a strategic push towards bringing its nanomedicine solutions to market. Future developments will likely involve advancing its drug candidates through clinical trials and scaling manufacturing capabilities to meet anticipated demand. The company's ability to tailor drug delivery and encapsulate therapeutic cells indicates a strong potential to disrupt multiple therapeutic areas, from oncology to regenerative medicine.
See full AllExcel company page
